Section Arrow
Quote
RNAZ.NASDAQ
- TransCode Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/20 13:13 EDT
Regular Hours
Last
 9.94
-0.11 (-1.09%)
Day High 
10.3753 
Prev. Close
10.05 
1-M High
10.3 
Volume 
35.54K 
Bid
9.3
Ask
9.9
Day Low
9.02 
Open
10.1 
1-M Low
6.8 
Market Cap 
8.38M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 8.98 
20-SMA 8.35 
50-SMA 8.04 
52-W High 822.36 
52-W Low 6.14782 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-792.40/-8.96
Enterprise Value
8.38M
Balance Sheet
Book Value Per Share
12.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 13:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.